Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $71,081.52 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Nadia Waheed sold 7,863 shares of the stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total value of $71,081.52. Following the transaction, the insider directly owned 318,417 shares in the company, valued at $2,878,489.68. The trade was a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ocular Therapeutix Stock Performance

Ocular Therapeutix stock traded down $1.89 during mid-day trading on Tuesday, reaching $6.99. 51,503,167 shares of the stock traded hands, compared to its average volume of 4,346,415. Ocular Therapeutix, Inc. has a 12-month low of $5.78 and a 12-month high of $16.44. The business’s 50-day moving average is $11.22 and its 200-day moving average is $11.78. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32. The stock has a market capitalization of $1.52 billion, a PE ratio of -4.85 and a beta of 0.90.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The business had revenue of $13.25 million during the quarter, compared to the consensus estimate of $16.13 million. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The business’s quarterly revenue was down 22.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.29) EPS. As a group, sell-side analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analysts Set New Price Targets

OCUL has been the topic of several analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $20.00 target price on shares of Ocular Therapeutix in a research report on Monday, December 8th. Royal Bank Of Canada reissued an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a report on Thursday, February 5th. TD Cowen restated a “buy” rating on shares of Ocular Therapeutix in a research note on Thursday, October 30th. Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Hedge Funds Weigh In On Ocular Therapeutix

Several institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Ocular Therapeutix by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 93,619 shares of the biopharmaceutical company’s stock valued at $686,000 after purchasing an additional 5,156 shares in the last quarter. Caxton Associates LLP bought a new stake in shares of Ocular Therapeutix in the 1st quarter worth about $248,000. KLP Kapitalforvaltning AS lifted its holdings in shares of Ocular Therapeutix by 36.2% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 23,700 shares of the biopharmaceutical company’s stock valued at $220,000 after acquiring an additional 6,300 shares during the last quarter. Allianz Asset Management GmbH grew its position in Ocular Therapeutix by 63.2% in the second quarter. Allianz Asset Management GmbH now owns 61,200 shares of the biopharmaceutical company’s stock worth $568,000 after acquiring an additional 23,700 shares in the last quarter. Finally, AlphaQuest LLC increased its stake in Ocular Therapeutix by 200.8% during the second quarter. AlphaQuest LLC now owns 20,196 shares of the biopharmaceutical company’s stock worth $187,000 after acquiring an additional 13,483 shares during the last quarter. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Key Stories Impacting Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 demonstrated statistical superiority to Regeneron’s Eylea on the trial’s vision endpoint, supporting Ocular’s plan to pursue an FDA filing and a potential new treatment option in wet AMD. Ocular Therapeutix’s eye drug superior to Regeneron’s Eylea in late-stage trial
• Positive Sentiment: Company and coverage note a clear regulatory path — Ocular is talking about an FDA submission based on the Phase 3 win, which could materially change the company’s product mix if approved. Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
• Neutral Sentiment: Ocular released topline SOL‑1 results and corporate commentary; the data readout itself is positive but investors are parsing subgroup/endpoint details and next steps. Ocular Therapeutix releases positive topline results from SOL-1
• Negative Sentiment: Despite the win, shares fell sharply because the observed benefit was characterized as modest and, crucially, the comparator in some analyses was a lower‑dose/less‑favorable version of Eylea — raising questions about clinical meaningfulness and commercial differentiation. Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron’s Eylea
• Negative Sentiment: Market and analyst coverage flagged investor skepticism — headlines note a 25–35% intraday decline on heavy volume as traders focused on practical uptake, labeling the result “positive but underwhelming.” Ocular claims a win with eye drug data even as shares sink
• Negative Sentiment: Commentary points to potential regulatory and commercial hurdles (e.g., demonstrating meaningful advantage vs standard‑dose Eylea, pricing/reimbursement, and adoption), which could delay or limit upside even if FDA accepts a filing. Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Regeneron’s leading Eylea

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.